221 related articles for article (PubMed ID: 12818222)
1. Farnesyl transferase inhibitors in myeloid malignancies.
Lancet JE; Karp JE
Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
[TBL] [Abstract][Full Text] [Related]
2. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Thomas X; Elhamri M
Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
Karp JE; Lancet JE
Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
Lancet JE; Karp JE
Blood; 2003 Dec; 102(12):3880-9. PubMed ID: 12920034
[TBL] [Abstract][Full Text] [Related]
5. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
6. Farnesyl transferase inhibitors in the treatment of breast cancer.
Kelland LR
Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl transferase inhibitors in myeloid disorders.
Lancet JE; Karp JE
Oncology (Williston Park); 2005 Jul; 19(8):1043-9; discussion 1049-50, 1053-4. PubMed ID: 16131046
[TBL] [Abstract][Full Text] [Related]
8. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Karp JE
Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors.
Hahn SM; Bernhard E; McKenna WG
Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
11. Farnesyl transferase inhibitors as anticancer agents.
Haluska P; Dy GK; Adjei AA
Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Baum C; Kirschmeier P
Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Dempke WC
Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305
[TBL] [Abstract][Full Text] [Related]
14. [New therapeutic targets and strategies in lung cancer].
Sánchez De Cos Escuín J
Arch Bronconeumol; 2002 Aug; 38(8):386-91. PubMed ID: 12199921
[No Abstract] [Full Text] [Related]
15. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
17. [Development of farsenyl transferase inhibitors as anticancer agents].
Cestac P; Doisneau-Sixou S; Favre G
Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
19. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
20. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]